The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 antigen for the prevention and treatment of sub-clinical PCV2 infection in animals, preferably in pigs. in the range of 920 to 960 kgm3 and an MFR1902 according to ISO 1133 in the range of 0. Examples of solvents include dimethoxyethane, dioxolane, and triethyleneglycol dimethyl ether. The mounting side has a tab for fastening.